loading page

The novel use of emapalumab and ruxolitinib in acquired malignancy-associated hemophagocytic lymphohistiocytosis in pediatric patients
  • Kenny Vo,
  • Jo Chung,
  • Arun Panigrahi
Kenny Vo
UC Davis Children's Hospital

Corresponding Author:khvo42@gmail.com

Author Profile
Jo Chung
University of California Davis
Author Profile
Arun Panigrahi
University of California Davis Department of Pediatrics
Author Profile


Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal syndrome of immune dysregulation that is classified into primary and secondary forms. The standard of care is established with dexamethasone and etoposide, but there are currently no guidelines for refractory HLH or cases triggered by infection or malignancy. [1] We describe here a series of pediatric patients with malignancy-associated HLH (m-HLH) to discuss the complexities in the initial diagnostic considerations, the balance of therapeutic regimens and their toxicities, and the novel use of emapalumab and ruxolitinib in patients with refractory disease.
21 Jul 2021Submitted to Pediatric Blood & Cancer
21 Jul 2021Assigned to Editor
21 Jul 2021Submission Checks Completed
22 Jul 2021Reviewer(s) Assigned
25 Aug 2021Review(s) Completed, Editorial Evaluation Pending
26 Aug 2021Editorial Decision: Revise Major